Ovagen
Also known as: Liver/ovary bioregulator, Glu-Asp-Leu
Ovagen (also called Liver/ovary bioregulator or Glu-Asp-Leu) is a khavinson bioregulator. Ovagen is a peptide preparation marketed in the Khavinson tradition, supplied as a complex of low-molecular-weight peptides extracted from animal tissue rather than as a single defined molecule. Because it is a mixture, no specific sequence, receptor or downstream pathway can be assigned, and the composition is not standardised between batches.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 375.37 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- Subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Liver / ovary (proposed)
Research summary
Peptide preparation sold in the Khavinson bioregulator tradition, supplied as a complex of low-molecular-weight peptides extracted from animal tissue rather than a single characterised compound. Sources disagree on which organ it is intended to support, which is itself a reason for caution when interpreting product claims. No controlled human evidence exists and it is not FDA-approved.
Peptide Library's Ovagen profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Vendor research protocols only
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Ovagen is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C15H25N3O8 |
|---|---|
| Molecular weight | 375.37 g/mol |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 444128 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Ovagen is a peptide preparation marketed in the Khavinson tradition, supplied as a complex of low-molecular-weight peptides extracted from animal tissue rather than as a single defined molecule. Because it is a mixture, no specific sequence, receptor or downstream pathway can be assigned, and the composition is not standardised between batches. The proposed mechanism is the series hypothesis of tissue-derived peptides influencing transcription in the corresponding tissue. Sources differ on which tissue this preparation targets, which is itself a reason for caution. No controlled human efficacy data exists.
Origin
Synthetic short peptide.
Targets
Studies
- Transvaginal follicular aspiration and embryo development in superstimulated early postpartum beef cows and subsequent fertility after artificial insemination
- Functions of characteristic Cys-Gly-His-Cys (CGHC) and Gln-Glu-Asp-Leu (QEDL) motifs of microsomal ER-60 protease
- Superovulation and embryo recovery in goats treated with Ovagen and Folltropin
- Reducing the bitterness of angiotensin-I-converting enzyme (ACE) inhibitory peptides from soybean protein by NADES-driven Maillard reaction
- Epitope Analysis of an Anti-Whale Podoplanin Monoclonal Antibody, PMab-237, Using Flow Cytometry
Regulatory & research status
Ovagen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Potential Side Effects
Side Effects
- Not characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Ovagen: frequently asked questions
What is Ovagen?
Peptide preparation sold in the Khavinson bioregulator tradition, supplied as a complex of low-molecular-weight peptides extracted from animal tissue rather than a single characterised compound. Sources disagree on which organ it is intended to support, which is itself a reason for caution when interpreting product claims. No controlled human evidence exists and it is not FDA-approved.
How does Ovagen work?
Ovagen is a peptide preparation marketed in the Khavinson tradition, supplied as a complex of low-molecular-weight peptides extracted from animal tissue rather than as a single defined molecule. Because it is a mixture, no specific sequence, receptor or downstream pathway can be assigned, and the composition is not standardised between batches.
Is Ovagen FDA approved?
No. Ovagen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Ovagen?
Compounds most often compared with Ovagen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Transvaginal follicular aspiration and embryo development in superstimulated early postpartum beef cows and subsequent fertility after artificial insemination — Anim Reprod Sci, 2010External reference
- Functions of characteristic Cys-Gly-His-Cys (CGHC) and Gln-Glu-Asp-Leu (QEDL) motifs of microsomal ER-60 protease — J Biochem, 1997External reference
- Superovulation and embryo recovery in goats treated with Ovagen and Folltropin — N Z Vet J, 1989External reference
- Reducing the bitterness of angiotensin-I-converting enzyme (ACE) inhibitory peptides from soybean protein by NADES-driven Maillard reaction — Food Chem, 2025External reference
- Epitope Analysis of an Anti-Whale Podoplanin Monoclonal Antibody, PMab-237, Using Flow Cytometry — Monoclon Antib Immunodiagn Immunother, 2020External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 2
This Ovagen profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Ovagen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →